Renalase, A Novel Regulator of Blood Pressure, Is Predicted by Kidney Function in Renal Transplant Recipients
Renalase, A Novel Regulator of Blood Pressure, Is Predicted by Kidney Function in Renal Transplant Recipients
复制标题
DOI：
10.1016/j.transproceed.2011.08.032
复制
发表时间：
2011-10-01
影响因子：
0.9
通讯作者：
Mysliwiec, M.
中科院分区：
文献类型：
--
作者：
Malyszko, J.;Zbroch, E.;Mysliwiec, M.
背景肾酶是一种分解代谢循环中的肾上腺素和去甲肾上腺素等儿茶酚胺的酶。人类肾脏将这种蛋白质释放到血液中以调节血压。在肾移植受者中，高血压的患病率为60%-80%。本研究的目的是评估89例肾移植受者肾酶、血压和肾功能之间可能的相关性。为了获得正常范围，我们还研究了27名健康志愿者的肾酶水平。在医院中心实验室通过标准实验室方法测量全血细胞计数、尿素、血脂、空腹血糖和肌酐。使用市售试剂盒对肾酶进行评估。肾移植受者肾酶显著高于健康志愿者（P <0.001）。肾移植受者肾酶与年龄相关（r = 0.29; P < .05），移植后时间（r = 0.34; P < .01），收缩压（r = 0.28; P < .05），舒张压（r = 0.27; P < .05），血清肌酐（r = 0.49; P < .001），估计肾小球滤过率（慢性肾脏病环境学合作：r = 0.44; P < .0001;肾脏病饮食改良：r = 0.43; P < .001; Cockcroft-Gault r = -0.39; P <0.01）、血磷（r = 0.34; P <0.05）。经多元回归分析，肾酶可通过年龄（β值0.21，P = 0.043）、移植后时间（β值0.22，P = 0.037）、血清肌酐（β值0.50，P = 0.016）和舒张压（β值0.33，P = 0.027）预测70%。肾酶在肾移植受者中高度升高，主要取决于肾功能，肾功能随肾移植后时间和年龄而恶化。需要进一步研究以确定其在移植后高血压发病机制中的假定作用以及可能的新靶向治疗。
Background. Renalase is an enzyme that catabolizes catecholamines such as adrenaline and noradrenaline in the circulation. The human kidney releases this protein into the bloodstream to regulate blood pressure. In kidney transplant recipients, the prevalence of hypertension is 60%-80%.Objective. The aim of our study was to assess possible correlations between renalase, blood pressure, and kidney function among 89 prevalent kidney allograft recipients. To obtain normal ranges, we also studied renalase levels in 27 healthy volunteers.Methods. Complete blood counts, urea, serum lipids, fasting glucose, and creatinine were measured by standard laboratory methods in the hospital central laboratory. Renalase was assessed with the use of a commei-cially available kit.Results. In kidney transplant recipients renalase was significantly higher than in healthy volunteers (P < .001). In kidney transplant recipients, renalase correlated with age (r = 0.29; P < .05), time after transplantation (r = 0.34; P < .01), systolic blood pressure (r = 0.28; P < .05), diastolic blood pressure (r = 0.27; P < .05), serum creatinine (r = 0.49; P < .001), estimated glomerular filtration rate (Chronic Kidney Disease Endemiology collaboration: r = 0.44; P < .0001; Modification of Diet in Renal Disease: r = 0.43; P < .001; Cockcroft-Gault r = -0.39; P < .01), serum phosphate (r = 0.34; P < .05). Upon multiple regression analysis renalase was predicted by 70% using age (beta value 0.21, P = 0.043), time after transplantation (beta value, 0.22; P = .037), serum creatinine (beta value, 0.50; P = .016), and diastolic blood pressure (beta value, 0.33; P = .027).Conclusions. Renalase is highly elevated in kidney transplant recipients, predominantly dependent on kidney function, which deteriorates with time after kidney transplantation and age. Further studies are needed to establish its putative role in the pathogenesis of hypertension after transplantation and possible novel targeted therapies.